FDA Approves Biogen, Eisai's Highly Anticipated Alzheimer's Treatment

investors.com/news/technology/biogen-eisai-under-the-skin-subcutaneous-leqembi-alzheimers-treatment

Biogen and Eisai won Food and Drug Administration approval of an at-home shot version of their Alzheimer's treatment Leqembi.
The post FDA Approves Biogen, Eisai's Highly Anticipated Alzheimer's Treatment appeared first on Investor's Business Daily.

This story appeared on investors.com, 2025-08-29 21:00:28.
The Entire Business World on a Single Page. Free to Use →